Kefu Medical to Raise Over HKD1B in H-Share Listing; Entry Fee HKD3,972.67; Lens Technology as Cornerstone Investor

Kefu Medical (01187.HK), a leading Chinese home medical device company already listed on the A-share market, will launch its IPO from today (27th) until 30th (Thu), offering a total of 27 million H shares globally, with 10% allocated to the Hong Kong public offering and 90% to the international placing. The maximum offer price is HKD39.33 per share, with a board lot size of 100 shares and an entry fee of HKD3,972.67. The shares are expected to be listed on May 6. Huatai International and BNP Paribas act as joint sponsors.The company has introduced 12 cornerstone investors, including Lens Technology (06613.HK) 0.000 (0.000%) Short selling $13.72M; Ratio 8.958% and Zhongkang Technology (02361.HK) 0.000 (0.000%) . The cornerstone investors have subscribed for a total of approximately USD48.49 million and will subscribe for 9.6543 million offer shares at the maximum offer price, representing approximately 35.76% of the total offer shares.Based on the maximum offer price of HKD39.33, the net proceeds from the listing are estimated to be approximately HKD1.007 billion. Of the proceeds, about 30% will be used for global expansion; about 30% for product research and development and technological innovation; about 20% for expanding domestic sales channels and distribution networks; about 10% for brand promotion and marketing activities; and the remaining 10% for working capital and general corporate purposes.According to a report by Frost & Sullivan, based on 2024 domestic revenue, Kefu Medical (301087.SZ) +0.850 (+1.576%) ranked second among all home medical device companies in China, with a market share of 2.1%. It ranked first in the home rehabilitation assistive devices segment, with a market share of 2.4%. As of the latest practicable date, its product portfolio covered more than 200 product categories and over ten thousand SKUs. The company has established partnerships with more than 80 "Top 100 Chain Pharmacies" enterprises and distributes its products through over 200,000 pharmacies.Financial data showed that for the year ended December 31, 2025, the company recorded revenue of RMB3.387 billion, representing a YoY increase of 13.6%. Profit for the year amounted to RMB370 million, up 18.6% YoY. Gross margin improved from 50.6% in 2024 to 51.7% in 2025. (ec/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-24 16:25.) (A Shares quote is delayed for at least 15 mins.)This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.